Abbisko Cayman Past Earnings Performance

Past criteria checks 0/6

Abbisko Cayman has been growing earnings at an average annual rate of 17.5%, while the Biotechs industry saw earnings growing at 31.7% annually. Revenues have been growing at an average rate of 2509% per year.

Key information

17.5%

Earnings growth rate

90.1%

EPS growth rate

Biotechs Industry Growth11.0%
Revenue growth rate2,509.0%
Return on equity-0.8%
Net Margin-3.3%
Last Earnings Update30 Jun 2024

Recent past performance updates

Recent updates

Companies Like Abbisko Cayman (HKG:2256) Can Afford To Invest In Growth

Sep 30
Companies Like Abbisko Cayman (HKG:2256) Can Afford To Invest In Growth

Here's Why We're Not Too Worried About Abbisko Cayman's (HKG:2256) Cash Burn Situation

Apr 27
Here's Why We're Not Too Worried About Abbisko Cayman's (HKG:2256) Cash Burn Situation

An Intrinsic Calculation For Abbisko Cayman Limited (HKG:2256) Suggests It's 37% Undervalued

Jan 09
An Intrinsic Calculation For Abbisko Cayman Limited (HKG:2256) Suggests It's 37% Undervalued

Will Abbisko Cayman (HKG:2256) Spend Its Cash Wisely?

Nov 01
Will Abbisko Cayman (HKG:2256) Spend Its Cash Wisely?

We Think Abbisko Cayman (HKG:2256) Can Afford To Drive Business Growth

Jun 08
We Think Abbisko Cayman (HKG:2256) Can Afford To Drive Business Growth

Revenue & Expenses Breakdown

How Abbisko Cayman makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

SEHK:2256 Revenue, expenses and earnings (CNY Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 24497-1691444
31 Mar 24258-22494439
31 Dec 2319-43296434
30 Sep 2319-457102429
30 Jun 2319-483108424
31 Mar 2310-489113402
31 Dec 220-496118379
30 Sep 2211-1,075129342
30 Jun 2223-1,654140306
31 Mar 2223-1,797144268
31 Dec 2123-1,810125226
31 Mar 217-77426155
31 Dec 200-70721133
31 Dec 194-1342281

Quality Earnings: 2256 is currently unprofitable.

Growing Profit Margin: 2256 is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 2256 is unprofitable, but has reduced losses over the past 5 years at a rate of 17.5% per year.

Accelerating Growth: Unable to compare 2256's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 2256 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (7.1%).


Return on Equity

High ROE: 2256 has a negative Return on Equity (-0.76%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/20 11:57
End of Day Share Price 2024/12/20 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Abbisko Cayman Limited is covered by 11 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jin ZhangChina International Capital Corporation Limited
Ziyu HeChina International Capital Corporation Limited
null nullChina International Capital Corporation Limited